Evaluation of the BD Phoenix M50 automated microbiology system for antimicrobial susceptibility testing with clinical isolates in Korea

Jun Sung Hong, Dokyun Kim, Da Young Kang, Byeol Yi Park, Sunmi Yang, Eun Jung Yoon, Hyukmin Lee, Seok Hoon Jeong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The objectives of this study were to evaluate the performance of the BD Phoenix™ M50 system with two antimicrobial susceptibility testing (AST) panels against clinical isolates in South Korea and the accuracy of determining carbapenem and colistin susceptibility compared with reference methods. A total of 825 nonduplicated clinical isolates were included in this study. Bacterial identification was performed using Bruker Biotyper and 16S rDNA sequencing. Antimicrobial susceptibilities were tested by disk diffusion, broth microdilution, and agar dilution methods. AST with the Phoenix system was performed following the manufacturer's instructions. The categorical agreement (CA), very major error (VME), major error (ME), and minor error (mE) rates were calculated for each antibiotic. CA rates between the results of the Phoenix system and reference methods were more than 90% for most antibiotics except for ciprofloxacin in enterococci (82.7%, 163/197) and cefepime in Acinetobacter species (88.9%, 88/99). VME and ME rates were less than 3% for all the antibiotics tested in this study. Minimum inhibitory concentration (MIC) values for carbapenem and colistin determined by the Phoenix system were highly correlated with those of dilution methods, exhibiting 99.2% (384/387), 96.7% (374/387), and 98.5% (129/131) of the agreement rate within onefold dilution difference for imipenem, meropenem, and colistin, respectively. The BD Phoenix M50™ system showed reliable performance for AST in clinical microbiology laboratories and for detecting carbapenem and colistin resistance in Gram-negative clinical isolates.

Original languageEnglish
Pages (from-to)1142-1148
Number of pages7
JournalMicrobial Drug Resistance
Volume25
Issue number8
DOIs
Publication statusPublished - 2019 Oct

Fingerprint

Colistin
Korea
Microbiology
Carbapenems
meropenem
Anti-Bacterial Agents
Republic of Korea
Acinetobacter
Imipenem
Enterococcus
Microbial Sensitivity Tests
Ciprofloxacin
Ribosomal DNA
Agar

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Pharmacology
  • Microbiology (medical)

Cite this

Hong, Jun Sung ; Kim, Dokyun ; Kang, Da Young ; Park, Byeol Yi ; Yang, Sunmi ; Yoon, Eun Jung ; Lee, Hyukmin ; Jeong, Seok Hoon. / Evaluation of the BD Phoenix M50 automated microbiology system for antimicrobial susceptibility testing with clinical isolates in Korea. In: Microbial Drug Resistance. 2019 ; Vol. 25, No. 8. pp. 1142-1148.
@article{acde9e97a59041629cb0597352f017b5,
title = "Evaluation of the BD Phoenix M50 automated microbiology system for antimicrobial susceptibility testing with clinical isolates in Korea",
abstract = "The objectives of this study were to evaluate the performance of the BD Phoenix™ M50 system with two antimicrobial susceptibility testing (AST) panels against clinical isolates in South Korea and the accuracy of determining carbapenem and colistin susceptibility compared with reference methods. A total of 825 nonduplicated clinical isolates were included in this study. Bacterial identification was performed using Bruker Biotyper and 16S rDNA sequencing. Antimicrobial susceptibilities were tested by disk diffusion, broth microdilution, and agar dilution methods. AST with the Phoenix system was performed following the manufacturer's instructions. The categorical agreement (CA), very major error (VME), major error (ME), and minor error (mE) rates were calculated for each antibiotic. CA rates between the results of the Phoenix system and reference methods were more than 90{\%} for most antibiotics except for ciprofloxacin in enterococci (82.7{\%}, 163/197) and cefepime in Acinetobacter species (88.9{\%}, 88/99). VME and ME rates were less than 3{\%} for all the antibiotics tested in this study. Minimum inhibitory concentration (MIC) values for carbapenem and colistin determined by the Phoenix system were highly correlated with those of dilution methods, exhibiting 99.2{\%} (384/387), 96.7{\%} (374/387), and 98.5{\%} (129/131) of the agreement rate within onefold dilution difference for imipenem, meropenem, and colistin, respectively. The BD Phoenix M50™ system showed reliable performance for AST in clinical microbiology laboratories and for detecting carbapenem and colistin resistance in Gram-negative clinical isolates.",
author = "Hong, {Jun Sung} and Dokyun Kim and Kang, {Da Young} and Park, {Byeol Yi} and Sunmi Yang and Yoon, {Eun Jung} and Hyukmin Lee and Jeong, {Seok Hoon}",
year = "2019",
month = "10",
doi = "10.1089/mdr.2018.0370",
language = "English",
volume = "25",
pages = "1142--1148",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

Evaluation of the BD Phoenix M50 automated microbiology system for antimicrobial susceptibility testing with clinical isolates in Korea. / Hong, Jun Sung; Kim, Dokyun; Kang, Da Young; Park, Byeol Yi; Yang, Sunmi; Yoon, Eun Jung; Lee, Hyukmin; Jeong, Seok Hoon.

In: Microbial Drug Resistance, Vol. 25, No. 8, 10.2019, p. 1142-1148.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the BD Phoenix M50 automated microbiology system for antimicrobial susceptibility testing with clinical isolates in Korea

AU - Hong, Jun Sung

AU - Kim, Dokyun

AU - Kang, Da Young

AU - Park, Byeol Yi

AU - Yang, Sunmi

AU - Yoon, Eun Jung

AU - Lee, Hyukmin

AU - Jeong, Seok Hoon

PY - 2019/10

Y1 - 2019/10

N2 - The objectives of this study were to evaluate the performance of the BD Phoenix™ M50 system with two antimicrobial susceptibility testing (AST) panels against clinical isolates in South Korea and the accuracy of determining carbapenem and colistin susceptibility compared with reference methods. A total of 825 nonduplicated clinical isolates were included in this study. Bacterial identification was performed using Bruker Biotyper and 16S rDNA sequencing. Antimicrobial susceptibilities were tested by disk diffusion, broth microdilution, and agar dilution methods. AST with the Phoenix system was performed following the manufacturer's instructions. The categorical agreement (CA), very major error (VME), major error (ME), and minor error (mE) rates were calculated for each antibiotic. CA rates between the results of the Phoenix system and reference methods were more than 90% for most antibiotics except for ciprofloxacin in enterococci (82.7%, 163/197) and cefepime in Acinetobacter species (88.9%, 88/99). VME and ME rates were less than 3% for all the antibiotics tested in this study. Minimum inhibitory concentration (MIC) values for carbapenem and colistin determined by the Phoenix system were highly correlated with those of dilution methods, exhibiting 99.2% (384/387), 96.7% (374/387), and 98.5% (129/131) of the agreement rate within onefold dilution difference for imipenem, meropenem, and colistin, respectively. The BD Phoenix M50™ system showed reliable performance for AST in clinical microbiology laboratories and for detecting carbapenem and colistin resistance in Gram-negative clinical isolates.

AB - The objectives of this study were to evaluate the performance of the BD Phoenix™ M50 system with two antimicrobial susceptibility testing (AST) panels against clinical isolates in South Korea and the accuracy of determining carbapenem and colistin susceptibility compared with reference methods. A total of 825 nonduplicated clinical isolates were included in this study. Bacterial identification was performed using Bruker Biotyper and 16S rDNA sequencing. Antimicrobial susceptibilities were tested by disk diffusion, broth microdilution, and agar dilution methods. AST with the Phoenix system was performed following the manufacturer's instructions. The categorical agreement (CA), very major error (VME), major error (ME), and minor error (mE) rates were calculated for each antibiotic. CA rates between the results of the Phoenix system and reference methods were more than 90% for most antibiotics except for ciprofloxacin in enterococci (82.7%, 163/197) and cefepime in Acinetobacter species (88.9%, 88/99). VME and ME rates were less than 3% for all the antibiotics tested in this study. Minimum inhibitory concentration (MIC) values for carbapenem and colistin determined by the Phoenix system were highly correlated with those of dilution methods, exhibiting 99.2% (384/387), 96.7% (374/387), and 98.5% (129/131) of the agreement rate within onefold dilution difference for imipenem, meropenem, and colistin, respectively. The BD Phoenix M50™ system showed reliable performance for AST in clinical microbiology laboratories and for detecting carbapenem and colistin resistance in Gram-negative clinical isolates.

UR - http://www.scopus.com/inward/record.url?scp=85073182761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073182761&partnerID=8YFLogxK

U2 - 10.1089/mdr.2018.0370

DO - 10.1089/mdr.2018.0370

M3 - Article

C2 - 31161952

AN - SCOPUS:85073182761

VL - 25

SP - 1142

EP - 1148

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 8

ER -